1
|
Mesny E, Jacob J, Culot F, Calugaru V, Jenny C, Fonti B, Bourdais R, Courtault-Deslandes F, Boulle G, Meillan N, Simon JM, Maingon P, Feuvret L. Optic nerve motion and gaze direction: Their impact on intraorbital tumor radiotherapy. Cancer Radiother 2022; 26:678-683. [DOI: 10.1016/j.canrad.2021.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 12/13/2021] [Indexed: 10/19/2022]
|
2
|
Romano E, Simon R, Martin V, Bolle S, Andraud M, Boulle G, Kissel M, Kumar T, Martelli H, Guerin F, Deutsch E, Haie-Meder C, Chargari C. OC-1045: Dose-volume effect relationships for rectal morbidity after brachytherapy for pediatric cancers. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01982-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
3
|
Grégoire V, Blanchard P, Allajbej A, Petit C, Milhade N, Nguyen F, Bakkar S, Boulle G, Romano E, Zrafi W, Lombard A, Ullmann E, Paragios N, Deutsch E, Robert C. OC-0681: Deep learning auto contouring of OAR for HN radiotherapy: a blinded evaluation by clinical experts. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00703-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Blanchard P, Gregoire V, Petit C, Milhade N, Allajbej A, Nguyen T, Bakkar S, Boulle G, Lombard A, Beldjoudi G, Munoz A, Ullman E, Paragios N, Deutsch E, Robert C. A Blinded Prospective Evaluation Of Clinical Applicability Of Deep Learning-Based Auto Contouring Of OAR For Head and Neck Radiotherapy. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.239] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Boulle G, Velut Y, Mansuet-Lupo A, Gibault L, Blons H, Fournel L, Boni A, Cremer I, Wislez M, Duchatelle V, Trédaniel J, Hammond SA, Herbst R, Alifano M, Giraud P, Damotte D. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma. Eur J Cancer 2020; 135:221-229. [PMID: 32610210 DOI: 10.1016/j.ejca.2020.04.040] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 04/18/2020] [Accepted: 04/27/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND Radiotherapy is a standard of care for locally advanced stage III N2 non-small-cell lung carcinoma (NSCLC) combined with surgery/chemotherapy. Radiotherapy is hypothesised to induce tumour immunogenic cell death, to release neoantigen resulting in intra-tumoural immune infiltration and abscopal effect. Conversely, it has not been demonstrated if immune cells are necessary to drive radiotherapy efficacy and predict patient's survival. PATIENTS AND METHODS We retrospectively analysed tumour samples and clinical data from 113 patients, 89 resected (PORT) and 24 non-resected (DRC) N2-NSCLC treated with chemotherapy and radiotherapy (same radiotherapy department from 2002 to 2015). The immune environment was characterised with in situ multiplex staining (CD8, FoxP3, PD-L1 and cytokeratin) and correlated with clinical data and survival. RESULTS High density of CD8+ T cells was associated with OS (p = 0.04, HR = 1.93 [0.99-3.78]) and DFS (p = 0.003, HR = 2.42 [1.31-4.47]) in the PORT. High density of CD8+/FoxP3+ double positive cells was associated with OS (p = 0.01, HR = 1.97 [1.11-3.48]) in the whole population, with OS (p = 0.05, HR = 1.92 [0.98-3.74]) and PFS (p = 0.03, HR = 1.83 [1.03-3.23]) in the PORT without reaching significance for the DRC. Intermediate PD-L1 expression in tumour cells (TPS = 1-49%) was associated with a higher survival in the PORT. CONCLUSIONS Intra-tumoural CD8+ T cell and particularly CD8+/FoxP3+ double positive T cell densities predict survival in stage III N2-NSCLC suggesting the need for a pre-existing intra-tumour immunity to mediate the action of radiotherapy. Density of CD8+/FoxP3+ cells was the best predictor of patient's survival in multivariate analysis and could represent a biomarker of radiotherapy efficacy.
Collapse
Affiliation(s)
- G Boulle
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France
| | - Y Velut
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France
| | - A Mansuet-Lupo
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France; Department of Pathology, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France
| | - L Gibault
- Department of Pathology, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France
| | - H Blons
- University Paris Descartes, Paris, France; INSERM UMRS 1147, Paris, France; Department of Biochemistry, APHP, Hôpital Européen Georges Pompidou, Paris, France
| | - L Fournel
- University Paris Descartes, Paris, France; Department of Thoracic Surgery, APHP, Hôpital Cochin, Paris, France; INSERM U1124, Paris, France
| | - A Boni
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France
| | - I Cremer
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France
| | - M Wislez
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; Department of Respiratory Medicine, APHP, Hôpital Cochin, Paris, France
| | - V Duchatelle
- Department of Pathology, St Joseph Hospital, Paris, France
| | - J Trédaniel
- University Paris Descartes, Paris, France; INSERM U1124, Paris, France; Department of Oncology, St Joseph Hospital, Paris, France
| | - S A Hammond
- Research and Early Discovery, Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA
| | - R Herbst
- Research and Early Discovery, Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA
| | - M Alifano
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France; Department of Thoracic Surgery, APHP, Hôpital Cochin, Paris, France
| | - P Giraud
- University Paris Descartes, Paris, France; APHP, Hôpital Européen Georges Pompidou, Department of Radiotherapy, Paris, France
| | - D Damotte
- Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France; Department of Pathology, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France.
| |
Collapse
|
6
|
Boulle G, Saint Martin C, Bidoz NF, Berger F, Veret A, Bragard C, Minsat M, Fourquet A, De La Lande B, Kirova Y. Long-Term Results of Post Mastectomy Conformal Electron Therapy Technique (PMERT) with Bolus in Comparison with Post Mastectomy Conformal Photon Therapy (PMPhRT) without Bolus in Non-Metastatic Breast Cancer Patients. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
7
|
Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer]. Rev Pneumol Clin 2018; 74:339-350. [PMID: 30337201 DOI: 10.1016/j.pneumo.2018.09.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Immune checkpoint inhibitors (ICI), targeting the PD1/PD-L1 axis has shown their efficacy in lung cancer but only in a restricted population of patients, thus it is mandatory to identify biomarkers predicting the clinical benefit. In this article we will describe and analyzed biomarkers already published, from protein, to RNA and at last DNA markers, discussing each markers feasibility and interest. In the future, combined analysis of several markers will probably be proposed, particularly with the increasing complexity of therapy schema with molecules association.
Collapse
Affiliation(s)
- A Lupo
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France; Service de pathologie, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - M Alifano
- Université Paris Descartes, 75006 Paris, France; Service de chirurgie thoracique, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - M Wislez
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France; Service de pathologie, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France; Service de pneumologie, hôpital Tenon, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - G Boulle
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France
| | - Y Velut
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France
| | - J Biton
- Laboratoire immunologie et immunopathologie-Li2P, Inserm UMR 1125, physiopathologie, cibles et thérapies de la polyarthrite rhumatoïde, Sorbonne Paris cité université Paris 13, 93000 Bobigny, France
| | - I Cremer
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France
| | - F Goldwasser
- Université Paris Descartes, 75006 Paris, France; Service d'oncologie médicale, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - K Leroy
- Université Paris Descartes, 75006 Paris, France; Service de génétique et biologie moléculaires, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - D Damotte
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France; Service de pathologie, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France.
| |
Collapse
|
8
|
Boulle G, Velut Y, Boni A, Lupo A, Alifano M, Trédaniel J, Giraud P, Damotte D. [Analysis of immune microenvironment by multiplex immunohistochemistry in locally advanced non-small cell lung cancer: Principles and perspectives]. Cancer Radiother 2018; 22:688-693. [PMID: 30131267 DOI: 10.1016/j.canrad.2018.07.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Accepted: 07/04/2018] [Indexed: 12/14/2022]
Abstract
Recent therapeutic advances in non-small cell lung cancer allow a better understanding of the interactions between the tumour and its direct immune environment. The identification of new immune biomarkers integrating both cell subpopulations and their interactions is a real issue in oncology. New techniques of tissue analysis, particularly multiplex immunohistochemistry, consisting of a labelling of several antigens of interest by immunofluorescence on the same slide, provide a better understanding of the tumour environment. Integration of these modalities of analysis to the therapeutic decision is promising, because it allows an increased characterization of each tumour, particularly interesting with radiotherapy and immunotherapy. This article describes the potential of these assays in locally advanced non-small cell lung cancer.
Collapse
Affiliation(s)
- G Boulle
- Centre de recherche des Cordeliers, Institut national de la santé et de la recherche médicale (Inserm), UMRS 1138, 15, rue de l'École-de-Médecine, 75006 Paris, France
| | - Y Velut
- Centre de recherche des Cordeliers, Institut national de la santé et de la recherche médicale (Inserm), UMRS 1138, 15, rue de l'École-de-Médecine, 75006 Paris, France
| | - A Boni
- Centre de recherche des Cordeliers, Institut national de la santé et de la recherche médicale (Inserm), UMRS 1138, 15, rue de l'École-de-Médecine, 75006 Paris, France
| | - A Lupo
- Centre de recherche des Cordeliers, Institut national de la santé et de la recherche médicale (Inserm), UMRS 1138, 15, rue de l'École-de-Médecine, 75006 Paris, France; Service d'anatomopathologie, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - M Alifano
- Service de chirurgie thoracique, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - J Trédaniel
- Service d'oncologie thoracique, groupe hospitalier Paris Saint-Joseph, 185, rue Raymond-Losserand, 75014 Paris, France
| | - P Giraud
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France
| | - D Damotte
- Centre de recherche des Cordeliers, Institut national de la santé et de la recherche médicale (Inserm), UMRS 1138, 15, rue de l'École-de-Médecine, 75006 Paris, France; Service d'anatomopathologie, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| |
Collapse
|
9
|
Boulle G, Bayle A, Deutsch E, Arnedos M, Rivera S. EP-1291: Clinical guidelines for breast cancer drugs and radiotherapy based on combination safety data. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31601-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
10
|
Hearse JD, Opie LH, Katzeff IE, Lubbe WF, Van der Werff TJ, Peisach M, Boulle G. Characterization of the "border zone" in acute regional ischemia in the dog. Am J Cardiol 1977; 40:716-26. [PMID: 920608 DOI: 10.1016/0002-9149(77)90187-4] [Citation(s) in RCA: 129] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|